TRANSFORMATIONAL VALUE :
Are we ready for radical change?
Basel : September 2018
New Jersey : April 2019
REAL WORLD EVIDENCE :
the new standard of proof
PERSONALISED MEDICINE :
moving from promise to practice
THE PATIENT EXPERIENCE IN CONTEXT : understanding its impact on
pharmaceutical strategies of the future
MARKET ACCESS : aligning regulatory
and commercial strategies
25th October 2017 | San Francisco, USA
- If the ultimate goal is to maximize therapeutic outcome and positive experience for the patient, what responsibilities should we embrace in order to make a constructive contribution?
- Everybody is claiming patientcentricity: What should our industry aspire to achieve?
John H. Powers, MD FACP FIDSA – Professor of Clinical Medicine at George Washington University School of Medicine
Andreas M. Pleil, Ph.D – Senior Director, Team Lead, Outcomes & Evidence Hematology Global Health & Value, Pfizer Inc.
Lulu McCartin, MBA – Business Insights & Analytics; Senior Executive, formerly Senior Director of Insights, Celgene
16 Clients attended
Amgen, Corcept Therapeutics, Eiger BioPharmaceuticals, Five Prime Therapeutics, ics Genentech, Jazz Pharmaceuticals, Revance Therapeutics, Theravance , Biophama, Ultragenyx